Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Marie Skłodowska-Curie Action · Ended early

BacTheRNA Bacterial-Derived Therapeutics based on CircRNAs (BacTheRNA)

Coordinator
University College Dublin, National University of Ireland, Dublin, Ireland
Runs
16 July 2022 to 15 May 2024
Status
Ended early
EU funding
€173k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101065819

What the project is doing

In the project's own words, from its summary on CORDIS.

RNA therapeutics are a rapidly growing field of research, thanks to their enormous potential. However, production costs and delivery systems represents the major issues for their widespread use in clinics. BacTheRNA aims at overcoming these issues by developing novel circular RNA (circRNA)-based therapeutics using recombinant food-grade bacteria. CircRNAs are advantageous over their linear counterpart, for their stability due to their intrinsic resistance to nucleases (which cannot cut circular molecules without free ends).

Their production costs are thus lower, as they do not need chemical or enzymatic modifications. Moreover, production in bacteria is simpler than chemical synthesis and it is scalable, with further reduced production costs. CircRNAs will be either purified as naked molecules or will be directly secreted by the bacteria in extracellular vesicles (EVs) embedding targeting moieties. Importantly, non-immunogenic circRNAs can be designed.

Intriguingly, BacTheRNA will demonstrate that it is possible to include targeting moieties directly through programming of circRNAs natural packaging, i.e. by expressing appropriate surface ligands on recombinant EVs. Finally, the potential to reach increased efficiency thanks to the possibility of amplification through rolling circle mechanisms is yet another innovative aspect of these next-generation RNA therapeutics.

As a proof-of-concept, circRNAs produced in BacTheRNA will be applied to Type 2 Diabetes Mellitus (T2DM) as a model target disease. Nevertheless, BacTheRNA will demonstrate a general strategy, which can potentially be exploited in several other pathologies that may benefit of RNA therapeutics approaches.

Topics

Who is involved

OrganisationCityCountryRole
University College Dublin, National University of Ireland, DublinDublinIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI